Published in Int J Radiat Oncol Biol Phys on March 01, 2010
Heart irradiation as a risk factor for radiation pneumonitis. Acta Oncol (2010) 1.20
Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry. J Oncol Pract (2013) 1.05
Esophageal toxicity from high-dose, single-fraction paraspinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys (2012) 1.00
STROGAR - STrengthening the Reporting Of Genetic Association studies in Radiogenomics. Radiother Oncol (2013) 0.97
Radiobiologically guided optimisation of the prescription dose and fractionation scheme in radiotherapy using BioSuite. Br J Radiol (2012) 0.96
Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys (2014) 0.95
Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer. Int J Radiat Oncol Biol Phys (2011) 0.95
Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer. Radiat Oncol (2013) 0.87
(Radio)biological optimization of external-beam radiotherapy. Comput Math Methods Med (2012) 0.87
Prescribed dose versus calculated dose of spinal cord in standard head and neck irradiation assessed by 3-D plan. South Asian J Cancer (2014) 0.85
Dosimetric predictors of esophageal toxicity after stereotactic body radiotherapy for central lung tumors. Radiother Oncol (2014) 0.84
Volume Modulated Arc Therapy (VMAT) for pulmonary Stereotactic Body Radiotherapy (SBRT) in patients with lesions in close approximation to the chest wall. Front Oncol (2013) 0.83
Technology for Innovation in Radiation Oncology. Int J Radiat Oncol Biol Phys (2015) 0.82
Helical tomotherapy for inoperable breast cancer: a new promising tool. Biomed Res Int (2013) 0.82
A simple plan evaluation index based on the dose to critical structures in radiotherapy. J Med Phys (2011) 0.81
Postoperative radiation therapy for non-small cell lung cancer and thymic malignancies. Cancers (Basel) (2012) 0.81
Patterns of CT lung injury and toxicity after stereotactic radiotherapy delivered with helical tomotherapy in early stage medically inoperable NSCLC. Br J Radiol (2015) 0.79
Moderately Escalated Hypofractionated (Chemo) Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer. Front Oncol (2013) 0.79
Dose to organs at risk in the upper abdomen in patients treated with extended fields by helical tomotherapy: a dosimetric and clinical preliminary study. Radiat Oncol (2013) 0.77
Comparative study of four advanced 3d-conformal radiation therapy treatment planning techniques for head and neck cancer. J Med Phys (2013) 0.77
Advancing our quantitative understanding of radiotherapy normal tissue morbidity. Acta Oncol (2014) 0.77
Personalized radiotherapy: concepts, biomarkers and trial design. Br J Radiol (2015) 0.77
Nonsurgical treatment for localized hepatocellular carcinoma. Curr Oncol Rep (2014) 0.76
Rationale and development of image-guided intensity-modulated radiotherapy post-prostatectomy: the present standard of care? Cancer Manag Res (2015) 0.76
Computational methods using genome-wide association studies to predict radiotherapy complications and to identify correlative molecular processes. Sci Rep (2017) 0.75
Identifying radiation-induced survivorship syndromes affecting bowel health in a cohort of gynecological cancer survivors. PLoS One (2017) 0.75
Using generalized equivalent uniform dose atlases to combine and analyze prospective dosimetric and radiation pneumonitis data from 2 non-small cell lung cancer dose escalation protocols. Int J Radiat Oncol Biol Phys (2012) 0.75
Dosimetric impact of different multileaf collimators on prostate intensity modulated treatment planning. Rep Pract Oncol Radiother (2015) 0.75
Impact of Fractionation and Dose in a Multivariate Model for Radiation-Induced Chest Wall Pain. Int J Radiat Oncol Biol Phys (2015) 0.75
Dose tracking assessment for image-guided radiotherapy of the prostate bed and the impact on clinical workflow. Radiat Oncol (2017) 0.75
Early experience of helical tomotherapy for hepatobiliary radiotherapy. Case Reports Hepatol (2011) 0.75
Delineation of clinical target volume for postoperative radiotherapy in stage IIIA-pN2 non-small-cell lung cancer. Onco Targets Ther (2016) 0.75
Treatment outcomes and patterns of radiologic appearance after hypofractionated image-guided radiotherapy delivered with helical tomotherapy (HHT) for lung tumours. Br J Radiol (2017) 0.75
Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys (1999) 4.24
Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys (2006) 3.40
A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys (2001) 2.85
Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys (2001) 2.71
Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer. Radiother Oncol (2006) 2.66
Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys (2005) 2.02
A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data. Int J Radiat Oncol Biol Phys (2007) 1.90
Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys (2000) 1.87
Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2006) 1.71
Towards evidence based radiation oncology: improving the design, analysis, and reporting of clinical outcome studies in radiotherapy. Radiother Oncol (1998) 1.70
Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. Int J Radiat Oncol Biol Phys (2006) 1.67
LENT SOMA tables. Radiother Oncol (1995) 1.65
Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.65
Radiation myelopathy following single courses of radiotherapy and retreatment. Int J Radiat Oncol Biol Phys (1994) 1.60
EORTC Late Effects Working Group. Late effects toxicity scoring: the SOMA scale. Radiother Oncol (1995) 1.58
Analysis of clinical complication data for radiation hepatitis using a parallel architecture model. Int J Radiat Oncol Biol Phys (1995) 1.54
Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys (2005) 1.49
Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys (2001) 1.39
The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol (2003) 1.37
Does radiation dose to the salivary glands and oral cavity predict patient-rated xerostomia and sticky saliva in head and neck cancer patients treated with curative radiotherapy? Radiother Oncol (2005) 1.31
Analysis of radiation pneumonitis risk using a generalized Lyman model. Int J Radiat Oncol Biol Phys (2008) 1.25
Dose-volume modeling of the risk of postoperative pulmonary complications among esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys (2006) 1.20
The atlas of complication incidence: a proposal for a new standard for reporting the results of radiotherapy protocols. Semin Radiat Oncol (2006) 1.18
Impact of volume and location of irradiated rectum wall on rectal blood loss after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys (2004) 1.09
Correlations between dose-surface histograms and the incidence of long-term rectal bleeding following conformal or conventional radiotherapy treatment of prostate cancer. Int J Radiat Oncol Biol Phys (2001) 1.08
Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer. Radiother Oncol (2002) 1.00
EORTC Late Effects Working Group. Overview of late effects normal tissues (LENT) scoring system. Radiother Oncol (1995) 0.99
Partial irradiation of the parotid gland. Semin Radiat Oncol (2001) 0.96
Calculation of the uncertainty in complication probability for various dose-response models, applied to the parotid gland. Int J Radiat Oncol Biol Phys (2001) 0.95
Gastrointestinal toxicity and its relation to dose distributions in the anorectal region of prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys (2005) 0.93
Spinal cord radiation tolerance. Int J Radiat Oncol Biol Phys (1994) 0.90
Partial irradiation of the rectum. Semin Radiat Oncol (2001) 0.88
Dose/volume relationship of late rectal bleeding after external beam radiotherapy for localized prostate cancer: absolute or relative rectal volume? Cancer J (2002) 0.88
Erratum to "Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer" [Radiother. Oncol. 78 (2006) 270-275]. Radiother Oncol (2006) 0.81
About tolerance and quality. An important notice to all radiation oncologists. Radiother Oncol (1995) 0.81
Correction for the use of the SOMA LENT tables. American and European LENT Working Committees. Radiother Oncol (1996) 0.79
Statistical analysis of dose-volume and dose-wall histograms for rectal toxicity following 3D-CRT in prostate cancer. Med Phys (2005) 0.78
EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol (2008) 5.46
Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol (2004) 4.63
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med (2013) 4.49
Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys (2010) 4.33
Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys (2009) 3.91
Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol (2005) 3.86
Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys (2010) 3.83
CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines. Radiother Oncol (2003) 3.78
Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys (2010) 3.73
Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol (2008) 3.55
Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys (2006) 3.40
Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys (2007) 3.34
Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol (2007) 3.16
Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol (2007) 3.08
Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol (2011) 3.04
Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys (2010) 2.94
How long have I had my cancer, doctor? Estimating tumor age via Collins' law. Oncology (Williston Park) (2011) 2.84
Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys (2012) 2.80
Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys (2010) 2.66
Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol (2005) 2.65
Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiat Oncol Biol Phys (2012) 2.55
Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol Biol Phys (2010) 2.48
Lack of osteoradionecrosis of the mandible after intensity-modulated radiotherapy for head and neck cancer: likely contributions of both dental care and improved dose distributions. Int J Radiat Oncol Biol Phys (2007) 2.48
Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol (2006) 2.45
Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys (2012) 2.41
Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol (2010) 2.41
Prone positioning causes the heart to be displaced anteriorly within the thorax: implications for breast cancer treatment. Int J Radiat Oncol Biol Phys (2008) 2.39
Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys (2010) 2.32
Variability of target and normal structure delineation for breast cancer radiotherapy: an RTOG Multi-Institutional and Multiobserver Study. Int J Radiat Oncol Biol Phys (2009) 2.27
Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol (2012) 2.24
PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys (2007) 2.21
Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: who's at risk? Int J Radiat Oncol Biol Phys (2008) 2.20
Parotid glands dose-effect relationships based on their actually delivered doses: implications for adaptive replanning in radiation therapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys (2013) 2.19
Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med (2010) 2.17
A microRNA expression signature for cervical cancer prognosis. Cancer Res (2010) 2.14
Radiation dose-volume effects of the urinary bladder. Int J Radiat Oncol Biol Phys (2010) 2.14
Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: safety profile for RTOG 0933. Radiother Oncol (2010) 2.12
Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res (2010) 2.11
A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy. Transl Oncol (2009) 2.10
Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer (2009) 2.08
Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol (2006) 2.00
Dose-effect relationships for the submandibular salivary glands and implications for their sparing by intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys (2008) 1.99
Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol (2003) 1.97
Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck. Radiother Oncol (2006) 1.95
Intensity-modulated radiation therapy for head and neck carcinoma. Oncologist (2007) 1.94
The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol (2008) 1.93
Whole brain radiotherapy with hippocampal avoidance and simultaneously integrated brain metastases boost: a planning study. Int J Radiat Oncol Biol Phys (2007) 1.91
A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data. Int J Radiat Oncol Biol Phys (2007) 1.90
Design and implementation of an anthropomorphic quality assurance phantom for intensity-modulated radiation therapy for the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys (2005) 1.90
Integral radiation dose to normal structures with conformal external beam radiation. Int J Radiat Oncol Biol Phys (2006) 1.88
Multivariable modeling of radiotherapy outcomes, including dose-volume and clinical factors. Int J Radiat Oncol Biol Phys (2006) 1.85
Progress toward a microradiation therapy small animal conformal irradiator. Med Phys (2006) 1.84
Radiation dose-volume effects in the esophagus. Int J Radiat Oncol Biol Phys (2010) 1.78
Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol (2013) 1.78
Local recurrence following initial resection of NSCLC: salvage is possible with radiation therapy. Cancer J (2006) 1.76
Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst (2010) 1.76
Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). J Am Coll Surg (2009) 1.76
Measurement of lung tumor motion using respiration-correlated CT. Int J Radiat Oncol Biol Phys (2004) 1.74
A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood (2009) 1.74
Assessment of the residual error in soft tissue setup in patients undergoing partial breast irradiation: results of a prospective study using cone-beam computed tomography. Int J Radiat Oncol Biol Phys (2007) 1.73
Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys (2010) 1.72
Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol (2006) 1.69
Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. Int J Radiat Oncol Biol Phys (2006) 1.67
Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: a report from the Children's Oncology Group. J Clin Oncol (2012) 1.67
Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. Int J Radiat Oncol Biol Phys (2005) 1.65
Intensity-modulated radiation therapy for oropharyngeal carcinoma: impact of tumor volume. Int J Radiat Oncol Biol Phys (2004) 1.64
Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst (2012) 1.64
Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer? Int J Radiat Oncol Biol Phys (2005) 1.64
Multi-institutional review of repeat irradiation of chest wall and breast for recurrent breast cancer. Int J Radiat Oncol Biol Phys (2007) 1.61
A new method for synthesizing radiation dose-response data from multiple trials applied to prostate cancer. Int J Radiat Oncol Biol Phys (2009) 1.59
A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. J Clin Oncol (2007) 1.55
One to three versus four or more positive nodes and postmastectomy radiotherapy: time to end the debate. J Clin Oncol (2008) 1.54
Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report. Int J Radiat Oncol Biol Phys (2005) 1.53
Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis. Semin Oncol (2005) 1.53
The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. Int J Radiat Oncol Biol Phys (2006) 1.52
Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys (2005) 1.49
Point: Hyperthermia with radiation for chest wall recurrences. J Natl Compr Canc Netw (2007) 1.49
4D-CT motion estimation using deformable image registration and 5D respiratory motion modeling. Med Phys (2008) 1.49
Long-term changes in pulmonary function tests after definitive radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys (2003) 1.49
A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatr Blood Cancer (2012) 1.49
Predicting radiotherapy-induced cardiac perfusion defects. Med Phys (2005) 1.47
Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer (2005) 1.47
Radiation therapy and hearing loss. Int J Radiat Oncol Biol Phys (2010) 1.46
Comparing radical prostatectomy and brachytherapy for localized prostate cancer. Oncology (Williston Park) (2004) 1.46
The use and QA of biologically related models for treatment planning: short report of the TG-166 of the therapy physics committee of the AAPM. Med Phys (2012) 1.46